Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia
References (19)
- et al.
Hepatitis C virus six years on
Lancet
(1994) - et al.
HLA haplotype A1 B8 DR3 as a risk factor for HIV-related disease
Lancet
(1988) - et al.
Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection
Gastroenterology
(1997) - et al.
Clinical evaluation of a single reaction, diagnostic polymerase chain reaction assay for detection of hepatitis C virus RNA
J Hepatol
(1996) - et al.
HLA typing in chronic type B, D and C hepatitis
J Hepatol
(1996) - et al.
The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic Non-A, Non-B Hepatitis Study Team
N Engl J Med
(1992) - et al.
Clinical outcomes after transfusion-associated hepatitis
N Engl J Med
(1995) - et al.
Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease
Hepatology
(1994) - et al.
Possible mechanisms involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection
Lancet
(1995)
Cited by (160)
Trans-ancestral fine-mapping of MHC reveals key amino acids associated with spontaneous clearance of hepatitis C in HLA-DQβ1
2022, American Journal of Human GeneticsCitation Excerpt :This is a multi-site international consortium including multiple studies from Europe and United States in which HCV infection outcomes were ascertained. They include ALIVE (AIDS Link to the Intravenous Experience),18 BBAASH (Baltimore Before and After Acute Study of Hepatitis),19 BAHSTION (Boston Acute Hepatitis C Virus Study: Transmission, Immunity and Outcomes Network),13 Cramp and colleagues’ study,20 HGDS (Hemophilia Growth and Development Study),21 Mangia and colleagues’ study,22 MHCS (Multicenter Hemophilia Cohort Study) and MHCS-II,23 REVELL (Correlates of Resolved Versus Low-Level Viremic Hepatitis C Infection in Blood Donors) study,24 the Swan Project,25 the Toulouse, France cohort,15 WIHS (Women’s Interagency HIV Study),26 the United Kingdom Drug Use cohort,27 and the Urban Health Study (UHS)28,29 as described in detail in elsewhere.5,6,17 These studies were selected because they had well-established hepatitis C virus (HCV) outcomes, as previously described,5,6,17 available DNA, and IRB approval for genetic testing.
Modeling primary biliary cholangitis and primary sclerosing cholangitis as infectious diseases
2022, Translational Autoimmunity: Challenges for Autoimmune Diseases: Volume 5Immunogenetics in the diagnosis of clinical disorders
2022, Immunogenetics: a Molecular and Clinical Overview: Clinical Applications of Immunogenetics, Volume IIIL-10 plays a central regulatory role in the cytokines induced by hepatitis C virus core protein and polyinosinic acid:polycytodylic acid
2016, International ImmunopharmacologyCitation Excerpt :However, polyI:C acted synergistically with HCV core protein to induce secretion of IL-10 in the monocytes but inhibited HCV core protein-induced TNF-α and IL-1β secretion (Fig. 1). To further characterize the phenotypes of monocytes induced by HCV core protein or polyI:C, flow cytometry was used to determine phenotypic expression, including human leukocyte antigen-D related (HLA-DR), cluster of differentiation 38 (CD38), and programmed death-ligand 1 (PD-L1), which reflect the host's immune response [23,24] related to HCV persistence [25–32]. We found that the optimal concentrations of HCV core protein and polyI:C for induction were 10 μg/mL and 50 μg/mL, respectively, and that the number of dead cells became fewer on day 2, resulting in better phenotypic expression.